Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
It'S Hanbul Co., Ltd. (226320.KS)
Seoul, KR
It'S Hanbul Co., Ltd., a South Korean entity established in 1989 and headquartered in Seoul, focuses on the research, production, and worldwide distribution of cosmetic goods. Operating globally, the company, which was known as It'S SKIN Co., Ltd. until its rebranding in 2017, provides a diverse array of beauty and personal care items. Its comprehensive skincare range includes toners, lotions, serums, gels, creams, emulsions, specialized effectors, eye treatments, sun protection, cleansing solutions, and various masks. For makeup, It'S Hanbul supplies foundational products like BB/CC creams, concealers, illuminators, foundations, and setting powders, in addition to accentuating items such as eye and lip care, eye shadows, brow products, nail care, blushes, and more highlighters. The company also offers body care essentials, including washes, scrubs, lotions, creams, fragrances, and hydrating mists/oils. Furthermore, its portfolio extends to hair care and styling products, dedicated lines for men and babies, hand and foot treatments, and an assortment of beauty accessories, including brushes and applicators.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.17% | -7.57% | +11.40% | -0.51% | +4.55% | -1.35% | +0.26% | -25.48% | -58.91% | -87.70% | -84.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%+7.7% ★ Q1'26: +17.5% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%-18.5% Q1'26: +322.8% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+10.7% ★ Q1'26: +6.1% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+12.5% ★ Q1'26: +16.0% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+10.3% ★ Q1'26: +14.8% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%+143.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×0.19× ★ Q1'26: 0.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
309.56B
est: 291.20B (+6.3%)
|
267.34B
est: 277.65B (-3.7%)
|
245.74B
est: 243.77B (+0.8%)
|
214.12B
est: 215.40B (-0.6%)
|
204.46B
est: 127.44B (+60.4%)
|
146.38B
est: 200.70B (-27.1%)
|
140.18B
est: 220.40B (-36.4%)
|
130.71B
est: 284.00B (-54.0%)
|
135.45B
est: 298.00B (-54.5%)
|
| EBITDA |
116.39B
est: 36.39B (+219.9%)
|
107.49B
est: 34.69B (+209.8%)
|
58.11B
est: 30.46B (+90.8%)
|
34.40B
est: 26.91B (+27.8%)
|
26.02B
est: 15.92B (+63.4%)
|
11.32B
est: 25.08B (-54.9%)
|
12.26B
est: 27.54B (-55.5%)
|
16.14B
est: 35.49B (-54.5%)
|
15.88B
est: 37.24B (-57.3%)
|
| EBIT |
111.75B
est: 24.03B (+365.0%)
|
99.74B
est: 22.91B (+335.3%)
|
49.79B
est: 20.12B (+147.5%)
|
26.91B
est: 17.78B (+51.4%)
|
18.68B
est: 10.52B (+77.6%)
|
4.59B
est: 16.56B (-72.3%)
|
5.57B
est: 18.19B (-69.4%)
|
10.61B
est: 23.44B (-54.7%)
|
11.21B
est: 24.59B (-54.4%)
|
| Net Income |
83.67B
|
58.35B
est: 64.31B (-9.3%)
|
27.50B
est: 27.26B (+0.9%)
|
8.24B
est: 8.54B (-3.6%)
|
7.44B
est: -2.29B (+424.7%)
|
-14.22B
est: 6.98B (-303.8%)
|
-17.44B
est: 10.15B (-271.8%)
|
-6.82B
|
3.40B
|
| SGA |
64.47B
est: 96.44B (-33.1%)
|
72.18B
est: 91.96B (-21.5%)
|
71.78B
est: 80.73B (-11.1%)
|
69.55B
est: 71.34B (-2.5%)
|
62.74B
est: 42.21B (+48.6%)
|
40.76B
est: 66.47B (-38.7%)
|
43.24B
est: 73.00B (-40.8%)
|
38.69B
est: 94.06B (-58.9%)
|
58.11B
est: 98.70B (-41.1%)
|
| EPS |
2,674.50
|
3,821.00
est: 3,650.50 (+4.7%)
|
1,851.00
est: 1,547.17 (+19.6%)
|
468.00
est: 485.00 (-3.5%)
|
422.14
est: -130.00 (+424.7%)
|
-806.93
est: 396.00 (-303.8%)
|
-989.94
est: 576.00 (-271.9%)
|
-387.46
|
192.80
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.01% | 46.7K | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jae-ok Jang | Senior MD & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 226320.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
